The effects of the oral beta agonist pirbuterol on pulmonary haemodynamics and gas exchange were studied in nine patients with severe irreversible airflow obstruction and moderate arterial hypoxaemia. limiting the rise in oxygen delivery to 21%. All changes were significant at the 2% level. These results show that pirbuterol dilates the pulmonary bed at the cost of a slight worsening of gas exchange, which is compensated by an independent rise in blood flow.
Quality of life-Two paediatric patients were excluded from the assessment of quality of life. The age ranges and average ages of the remaining patients in the three groups were: blind patients 25-64 years, average 40 4; sighted diabetic patients 31-63 years, average 46-7; non-diabetic patients 18-84 years, average 53 0. From the records a detailed summary of each patient was prepared and discussed by a conference of doctor, nurses, social worker, and dietitian. No specialised psychological data were used other than a detailed familiarity with each patient and closest relative. We agreed that continuous ambulatory peritoneal dialysis had not been worth while in eight non-diabetic patients and four sighted diabetics. Reasons varied but included patient resentment, recurrent peritonitis, failure to achieve self care, failure to achieve a satisfactory level of wellbeing, and early failure of the technique, causing the treatment to be abandoned. By contrast, we considered that continuous ambulatory peritoneal dialysis had been worth while in all the blind patients. One blind patient remained depressed but continued to do the exchanges himself without difficulty and refused to return to haemodialysis. Only one blind patient could not manage self care, because of neuropathy and dependency. His wife found continuous ambulatory peritoneal dialysis much less demanding on her than bringing him for haemodialysis, and so we considered the treatment worth while. For the rest of the blind patients the conclusion was positive. All returned to their previous employment, home making, or studying full time and functioned at the same level as before becoming ill with renal failure.
Other aspects of treatment-Biochemical and physical changes, blood sugar control, complications other than peritonitis, and variations in blood pressure are detailed elsewhere.6
Discussion
All the patients in this series were offered treatment and chose continuous ambulatory peritoneal dialysis. Most of them had received haemodialysis and all were considered for transplantation. Having chosen continuous ambulatory peritoneal dialysis, most of the blind patients achieved exemplary self care over extended periods. No better demonstration of a strong will to live, a keen interest in their own wellbeing, and a wish not to burden others could be asked of any patient. These patients obviously needed excellent training by skilled nurses and continuing support by the medical team. In return the team received much professional satisfaction. Probably the apathy and depression of blind diabetics with renal failure arise from their belief that they are thought of as hopeless cases. Any lingering sentiment that blindness in itself contraindicates treatment paralyses the doctor-patient relationship, to which I can testify, from the evolution of my own attitude. Of far more importance in inhibiting treatment in Britain must surely be the shortage of facilities and staff. There are many valid reasons for withholding treatment in diabetic patients with multiple complications, but when the blind patient chooses to have treatment it usually proves worth while.
Introduction
In patients with chronic airflow obstruction pulmonary hypertension is a bad prognostic sign.14 Long term oxygen treatment reduces mean pulmonary artery pressure in these patients, and in less severely affected patients oxygen improves the prognosis.5 Probably the oxygen acts by reversing hypoxic vasoconstriction. If so, other pulmonary vasodilators that are easy to administer long term might have the same effect. We therefore studied the effects of the acute administration of oral pirbuterol on pulmonary haemodynamics and gas exchange in nine patients who had severe airflow obstruction but only moderate hypoxaemia. Pirbuterol is a new beta agonist with both inotropic and vasodilative properties 7 which has been shown to be a useful adjunct to digoxin and diuretics in left heart failure.81-'
Patients and methods
We studied nine patients with chronic bronchitis (seven men, two women; age 45-75 years) whose mean forced expiratory volume in one second averaged 28°o of predicted values (range 15-48%).
They had arterial hypoxaemia (mean arterial oxygen pressure (Pao2) 8-4 (SE 0-5) kPa; 63 (SE 4) mm Hg) but were normocapnic (mean arterial carbon dioxide pressure (Paco2) 5 5 (SE 0-3) kPa; 41 (SE 2) mm Hg). None of the patients had had an infective exacerbation of their illness in the two months before the study and all had been receiving the same maintenance treatment (bronchodilators, steroids, diuretics) for at least one month. Oral beta agonists and methylxanthine preparations were stopped 24 hours before the study and inhalers were stopped on the day of the study. 1179 three minutes of straight leg raising to look for an exercise induced rise in PAP. Once the baseline values had been established (or re-established) 15 mg pirbuterol was given by mouth and measurements made every 30 minutes for 150 minutes. In the three patients who had been exercised the exercise was repeated at 100 minutes to see whether pirbuterol could prevent an exercise induced rise in PAP. Figure 2 gives the results for PAP, heart rate, and systemic blood pressure. The mean PAP for the group was moderately raised at 23 mm Hg. After pirbuterol the PAP fell at 30 and 60 minutes but these falls did not reach significance. The rise in PAP with exercise that occurred in all three patients in whom it was measured, however, was prevented in two of them. Heart rate rose at 30 minutes, reaching a maximum at 60 minutes (p < 0-02 to an average of 4-46 at 30 minutes. This rise of 210°, (SE 60') was significant (p<0002) and was accompanied by a 50o, rise in mixed venous oxygen pressure, which was also significant (p < 0 05). Spirometry was not repeated after the acute administration of pirbuterol but was repeated after the patients had been receiving the drug for two weeks. Functionally significant bronchodilatation was seen in only one of the nine subjects. 
Group

Discussion
This study shows that the acute administration of 15 mg pirbuterol by mouth to patients who have irreversible airflow obstruction but only moderate arterial hypoxaemia causes a significant fall in pulmonary vascular resistance at the cost of a significant fall in arterial oxygen pressure.
The mean cardiac output of our patients was 4-8 1/min, which is normal. This is a typical finding in patients with chronic airflow obstruction. Pirbuterol caused a rise in cardiac output without any significant change in pulmonary artery pressure. These results are in line with those of other studies (including two from our laboratory '2 13) where vasodilative drugs were given to patients with primary and secondary pulmonary hypertension. The fall in pulmonary vascular resistance was therefore accompanied by an increase in cardiac work, which is a function of cardiac output and pulmonary artery pressure. Whether the beneficial effects of a decrease in pulmonary vascular resistance are outweighed by the possibly harmful effects of an increase in cardiac work when drugs such as pirbuterol are given long term remains to be seen. The advantage of preventing an exercise induced rise in pulmonary artery pressure is at present theoretical.
The haemodynamic effects of pirbuterol occurred at the expense of a small but significant fall in arterial oxygen pressure. This fall is not surprising, because alveolar hypoxia causes a functional vasoconstriction to underventilated areas of the lung. Reversal of this vasoconstriction would result in worsening of ventilation-perfusion mismatch with adverse consequences for gas exchange. The fall in arterial oxygen pressure in our patients was unimportant because they were on the plateau of the oxygen dissociation curve. In patients with severe daytime hypoxaemia or those who desaturate severely at night a similar fall would have a greater impact on arterial oxygen content.
Bergofsky'1 argued that oxygen delivery to the tissues may be more important than arterial oxygen pressure. In our patients there was a significant rise in oxygen delivery despite the fall in arterial oxygen pressure because of the increase in cardiac output. This rise in coefficient of oxygen delivery resulted in a useful increase in mixed venous oxygen pressure, but it was impossible to determine which tissue or even which organ received the benefit of the increase in oxygen delivery.
Bergofsky also argued that an increase in cardiac output may be the distinguishing feature of those patients with chronic airflow obstruction who survive the longest. He suggested that attempts should be made to maintain cardiac output in patients with chronic bronchitis and emphysema by giving them drugs with inotropic or afterload reducing properties, or both. Pirbuterol is such a drug. Long term studies are needed to see whether its use will improve survival in these patients. A study of pulmonary vascular resistance in children with congenital heart disease. Thorax (in press). It comforts the heart, cherishes the vital spirits, resists the pestilence, and all corrupt airs, which indeed are the natural causes of epidemical diseases, the sick may take a spoonful of it in any convenient cordial, and such as are in health, and have bodies either cold by nature, or cooled by age, may take as much either in the morning fasting, or a little before meat. (Nicholas Culpeper (1616-54) The Complete Herbal, 1850.)
